NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / Technology News / UK teenager undergoes first global trial of skull-fitted epilepsy device
    Summarize
    Next Article
    UK teenager undergoes first global trial of skull-fitted epilepsy device
    The epilepsy device has led to significant improvement in his day-to-day life

    UK teenager undergoes first global trial of skull-fitted epilepsy device

    By Akash Pandey
    Jun 24, 2024
    02:14 pm

    What's the story

    Oran Knowlson, a 13-year-old boy from Somerset, UK, has become the first patient worldwide to trial a new epilepsy device implanted in his skull.

    Knowlson was diagnosed with Lennox-Gastaut syndrome, an epilepsy form resistant to treatment, at age three.

    Since then, he has endured multiple daily seizures, ranging from dozens to hundreds.

    The neurostimulator, known as Picostim and developed by UK-based Amber Therapeutics, has led to an 80% reduction in Knowlson's daytime seizures.

    Medical breakthrough

    Device trial conducted at renowned UK hospital

    Epilepsy seizures arise from abnormal bursts of electrical activity in the brain.

    The neurostimulator, such as Picostim, emits a constant pulse of current to block or disrupt these abnormal signals.

    The surgery, which lasted for eight hours, took place in October 2023 at Great Ormond Street Hospital in London as part of the Children's Adaptive Deep brain stimulation for Epilepsy Trial (CADET) project.

    The CADET initiative aims to assess the safety and effectiveness of deep brain stimulation for severe epilepsy.

    Implantation process

    How was the surgery done?

    The team at Great Ormond Street Hospital inserted two electrodes deep into Knowlson's brain, targeting the thalamus — a critical relay station for neuronal information.

    The ends of the leads were connected to the neurostimulator, a device measuring 3.5cm long and 0.6cm thick, positioned in a gap in Knowlson's skull where the bone had been removed.

    The neurostimulator was then secured by screwing it into the surrounding skull to ensure it remained in place.

    Recovery phase

    Significant improvement in epilepsy symptoms post-surgery

    Following a month-long recovery period after the operation, Knowlson's neurostimulator was activated.

    When the device is on, he experiences no sensation and can conveniently recharge it daily via wireless headphones.

    Seven months post-surgery, his mother reported a significant improvement in his epilepsy symptoms, with no daytime drop seizures and less severe night-time seizures.

    Knowlson is now happier and enjoys a "much better quality of life" since the surgery, his mother told BBC.

    Next phase

    Real-time response to brain activity

    The future plan for the neurostimulator involves real-time response to changes in brain activity, aiming to block seizures as they are about to happen.

    Knowlson's mother expressed excitement about this next phase of the trial, stating that "the Great Ormond Street team gave us hope back...now the future looks brighter."

    While the treatment is not a cure, Knowlson's family remains hopeful that he will continue to see improvements in his condition.

    Optimistic outlook

    The neurostimulator: A beacon of hope for severe epilepsy

    Knowlson also has autism and ADHD, though his mother emphasizes that his epilepsy has posed the greatest challenge.

    The neurostimulator has already significantly reduced his seizures and improved his quality of life.

    As part of the ongoing trial, three more children with Lennox-Gastaut syndrome will be fitted with the deep brain neurostimulator.

    This pioneering trial represents a significant step forward in the management of severe epilepsy, offering hope to many families around the world.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    United Kingdom
    Health & Wellness

    Latest

    Mohammad Abbas clocks his 49th five-wicket haul in FC cricket County Cricket
    IPL 2025, DC beat PBKS: Presenting Player of the Day Delhi Capitals (DC)
    'Criminal Justice' S04: Cast, plot, and release details Pankaj Tripathi
    IPL 2025, DC beat PBKS: How the Impact Players fared KL Rahul

    United Kingdom

    US reacts to Musk backing permanent UNSC seat for India Elon Musk
    Rising smartphone ownership among UK toddlers sparks concern United States of America
    US vetoes Palestinian bid to gain statehood at UN  Israel
    Dubai rain: Indian embassy in UAE issues advisory for passengers United Arab Emirates

    Health & Wellness

    Study finds elevated uranium, lead levels in teen vapers Research
    Laron syndrome's genetic mutation can protect people from aging Research
    Nourish your gut with these root veggies Lifestyle
    Quit Neuralink over safety concerns, says co-founder Dr. Benjamin Rapoport Neuralink
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025